Meridian set to acquire Gull for $25 million
This article was originally published in Clinica
Meridian Diagnostics has agreed in principle to buy Gull Laboratories, which is 62%-owned by German company Fresenius, for $3 per share in cash, in a deal worth around $25 million. Gull and Fresenius revealed two weeks ago that negotiations were underway with an unnamed company when Gull announced it expected to record a substantial loss in the second quarter (see Clinica No 817, p 9).
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.